AKT1 and liver cancer: In doxorubicin-resistant liver cancer (BEL-7402/ADM) cells, apigenin restores drug sensitivity by reducing nuclear factor erythroid 2-related factor 2 (NRF2) expression at both RNA and protein levels through PI3K/AKT pathway inhibition, thereby increasing intracellular doxorubicin [58, 59].